




Immunoproteasome in neuroinflammation

Michele Mishto

Institut für Biochemie
Universitätsmedizin Berlin- Charité




Protein targets of the Ubiquitin-proteasome system (UPS)




Bellavista et al, 2014

Functions of UPS




Wolf and Hilt, 2004


Proteasome isoforms



Constitutive proteasome



Immunoproteasome



Thymoproteasome

$\beta 1$ (PSMB6, γ , δ)

$\beta 2$ (PSMB7, Z, MCI4)

$\beta 5$ (PSMB5, X, MBI, ϵ)

$\beta 1i$ (PSMB9, LMP2)

$\beta 2i$ (PSMB10, LMP10, MECL1)

$\beta 5i$ (PSMB8, LMP7)

$\beta 1i$ (PSMB9, LMP2)

$\beta 2i$ (PSMB10, LMP10, MECL1)

$\beta 5t$ (PSMB11)

Catalytic subunits

Quantitatively different cleavage specificity makes immunoproteasome specifically involved in:

Cytokine-mediated inflammation


Cell-mediated immune response and lymphoid cell repertoire

Antigen presentation

Groettrup et al., 2010; Mishto et al., 2014

Immunoproteasome in CNS upon ageing


Immunoproteasome is almost absent in healthy young CNS but it is expressed in CNS upon ageing




Mishto et al., 2006; Giannini et al., 2013

Immunoproteasome in Alzheimer disease


β 1i immunosubunit - Human hippocampus





wt vs APPswePS1dE9 mouse hippocampus



Immunoproteasome expression in microglia and astrocytes



Immunoproteasome β 5i inhibition reduces pro-inflammatory signalling in AD microglia



Mishto et al., 2006; Orre et al., 2013


Human FCD / TLE hippocampus

Focal cortex dysplasia - $\beta 1i$ immunosubunit



1. Endotelial cells
2. Glia
3. Granular neurons
4. Pyramidal neurons





Mesial temporal lobe epilepsy - $\beta 5i$ immunosubunit



Mishto et al., 2010

Immunoproteasome in pharmacoresistant epilepsies



Pilocarpine-induced epileptic rat hippocampus




Mishto et al., 2015

Immunoproteasome in pharmacoresistant epilepsies

Pilocarpine-induced epileptic rat hippocampus




HMGB1-mediated activation of TLR-4 leads to immunoproteasome expression



Mishto et al., 2015

Immunoproteasome in pharmacoresistant epilepsies



Pilocarpine-induced epileptic rat hippocampus





Mishto et al., 2015

Immunoproteasome in pharmacoresistant epilepsies

Pilocarpine-induced epileptic rat hippocampus



β 5i immunosubunit inhibition suppresses or delays SLEs in epileptic rats




β 5 subunit inhibition has no or mild effects on SLEs in epileptic rats

Mishto et al., 2015

Immunoproteasome in multiple sclerosis


Staining of $\beta 1i$ immunosubunit



Rostral medulla with MS palques



Parietal lobe of MS patient




Mishto et al., 2010


Immunoproteasome in multiple sclerosis

Effect by acting on myelin antigen presentation?

Genotype	MS (n = 337)	control (n = 202)	p	OR (95% CI)
HH	26 (7.7)	32 (15.8)		
RH	146 (43.3)	80 (39.6)	0.013	
RR	165 (49.0)	90 (44.6)		
HH vs RR			0.005	0.443 (0.249–0.790)
HH vs RH			0.006	0.445 (0.248–0.799)



HLA-A*0201+ subjects carrying the 60H polymorphism in β 1i immunosubunit are less prone to develop MS





In vitro production of HLA-A*0201-restricted **MBP₁₁₁₋₁₁₉ epitope** by 60H⁺ or 60H⁻ β 1i immunosubunit

Mishto et al., 2010

Immunoproteasome in multiple sclerosis

Effect by acting on cytokine circuits?



Bellavista et al., under review

Summary

Immunoproteasome expression is induced in different CNS cell types:

- during ageing
- in AD patients
- in epileptic patients
- in Multiple Sclerosis patients

Immunoproteasome expression is involved in neuropathologies in:

- cytokine-mediated inflammation
- pathology-associated antigen presentation
- neuronal activity

The pathology-specific expression of immunoproteasome makes specific immunoproteasome inhibitors interesting for therapy.

Acknowledgements



Institut für Biochemie

Kathrin Textoris-Taube

Christin Keller

Peter Kloetzel

Institut für

Neurophysiologie

Muhammad L. Raza

Uwe Heinemann

Neurocure

Klemens Rupprecht

Friedemann Paul

**Imperial College
London**

Juliane Liepe

Michael Stumpf



UNIVERSITÀ DEL PIEMONTE ORIENTALE

Luca Gigliotti

Annalisa Chiocchetti

Cristoforo Comi

Umberto Dianzani



UNIVERSITÀ
DEGLI STUDI
DI MILANO

Daniela Galimberti



ISTITUTO SCIENTIFICO UNIVERSITARIO
SAN RAFFAELE

Melissa Sorosina

Filippo Martinelli Boneschi



Teresa Ravizza

Annamaria Vezzani



Elena Bellavista

Dario de Biase

Francesco Vasuri

Annalisa Pession

Funding bodies:

- Young Researcher fund 2007 - Italian Minister of Health

- FIRE fund 2012 - Fondazione Italiana Ricerca sull'Epilessia

- Onyx Pharmaceutical fund 2012 (subsidiary of Amgene)



UNIVERSITÀ
DEGLI STUDI
DI TORINO


Chiara Dianzani



Consiglio
Nazionale delle
Ricerche

Claudia Verderio

Proteasomes and antigens presentation



Strehl et al, 2005